While our study supports this triple therapy for ARID1A-hypermethylated gastric cancer, its clinical use requires careful toxicity management: Blood-related side effects from 5-aza-CdR can be reduced using lower doses (0.1 mg/kg) (Zhao et al., 2025). This evidence concerns the gene ARID1A and gastric cancer.